Univercells Expands Its Development Capacity with Modular Laboratories

Univercells, a business-to-business provider focused on increasing the availability of affordable vaccines and biotherapeutics, deploys over 400 m² its vaccine development capacity using prefabricated and versatile laboratories. The company inaugurates this flexible facility by accommodating the development of its polio, measles, rubella and other key vaccines solutions.

Providing great flexibility, these modular laboratories represent an excellent solution to rapidly deploy and adapt additional laboratory capacity. These portable structures are pre-fabricated off-site, delivered and assembled as a full laboratory environment comprising all required equipment and utilities. Permanent or temporary facilities can thus be established in existing or new infrastructure in a timely and cost-effective manner.

A first set of Biosafety Level 3 (BSL-3) laboratories was installed at Univercells in a year from initial design to final validation, vs. over two years for conventional constructions. An additional BSL-2 laboratory complements the facility, for a total cleanroom area of over 400 m² accommodating approximately 20 scientists and technicians.

With this flexible viral development facility in Nivelles, Univercells is now fully operational to deliver a vaccine portfolio to be produced at an affordable cost using its NevoLine™ biomanufacturing platform.

“Modular labs and cleanrooms are easily transportable and offer cost-effective, low-footprint facilities, an ideal solution to rapidly accommodate Univercells' growth.”, commented Hugues Bultot, CEO and co-founder of Univercells. “We are excited to implement this technology internally, and we believe it will be particularly suited to deliver our NevoLine biomanufacturing solutions globally, enabling manufacturers to rapidly implement sustainable production units locally.”